As of Wednesday, Pear Therapeutics Inc.’s (NASDAQ:PEAR) stock closed at $1.98, up from $1.90 the previous day. While Pear Therapeutics Inc. has overperformed by 4.21%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PEAR fell by -80.14%, with highs and lows ranging from $14.60 to $1.34, whereas the simple moving average fell by -34.12% in the last 200 days.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
On January 26, 2022, BofA Securities started tracking Pear Therapeutics Inc. (NASDAQ: PEAR) recommending Neutral. A report published by Credit Suisse on January 20, 2022, Initiated its previous ‘Outperform’ rating for PEAR. BTIG Research also rated PEAR shares as ‘Buy’, setting a target price of $12 on the company’s shares in an initiating report dated January 03, 2022. Citigroup Initiated an Buy rating on December 29, 2021, and assigned a price target of $13. Chardan Capital Markets initiated its ‘Buy’ rating for PEAR, as published in its report on December 22, 2021.
Analysis of Pear Therapeutics Inc. (PEAR)
Further, the quarter-over-quarter increase in sales is 211.40%, showing a positive trend in the upcoming months.
One of the most important indicators of Pear Therapeutics Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 2.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and PEAR is recording 433.08K average volume. On a monthly basis, the volatility of the stock is set at 12.18%, whereas on a weekly basis, it is put at 10.61%, with a gain of 3.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.26, showing growth from the present price of $1.98, which can serve as yet another indication of whether PEAR is worth investing in or should be passed over.
How Do You Analyze Pear Therapeutics Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.12%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 73.40% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in PEAR shares?
The recent increase in stakes in PEAR appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc. made another increased to its shares in PEAR during the first quarter, upping its stake by 199.92%. During the last quarter, the company picked up 2,098,834 additional shares for a total stake of worth $8.66 million, bringing number of shares owned by the company to 3,148,670.
At the end of the first quarter, Geode Capital Management LLC increased its PEAR holdings by 198.16% and now holds 1.04 million PEAR shares valued at $2.85 million with the added 0.69 million shares during the period. PEAR shares are owned by institutional investors to the tune of 73.40% at present.